Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Rani Therapeutics Holdings Q3 2026 Results: Net Loss of $7.73M, Loss Widens

Rani Therapeutics reported contract revenue of $5.1 million for the nine months ended September 30, 2026, a significant increase from $0.2 million in the prior year. Despite the revenue growth, the company recorded a net loss as total operating expenses reached $31.5 million, driven by increased research and development activities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.70.0
Net income-7.7-5.4
EPS (diluted, $ a share)$-0.04$-0.12

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: RANI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Rani Therapeutics Holdings, Inc.: key numbers

Share price
$0.5403Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Rani Therapeutics Holdings, Inc.

All →
4:21 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Rani Therapeutics Holdings Nasdaq/NYSE Compliance Notice

Rani Therapeutics received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. As part of this process, the company's listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective November 12, 2026. The company now has until May 10, 2027, to meet the requirement, which may involve a reverse stock split if necessary.

Counterparty
Nasdaq
Term
180 days
5:04 PM ET 8-K
Financial Results

Rani Therapeutics Holdings Financial Results

Rani Therapeutics reported third quarter 2026 financial results and announced its acceptance into the FDA’s Emerging Technology Program to support the RaniPill platform. The company reported a cash position of $45.3 million, which it expects will fund operations through the end of 2027, and noted that enrollment continues for its RT-114 Phase 1a expansion cohort.

“The third quarter marked continued progress for the RaniPill® platform and, most recently, our acceptance into the FDA’s Emerging Technology Program in October provides an opportunity to engage with the Agency on technical, manufacturing and regulatory considerations related to the RaniPill® platform.”

Talat Imran, Chief Executive Officer of Rani Therapeutics

“With cash, cash equivalents and marketable securities of $45.3 million, we believe we are well positioned to fund operations at least through the end of 2027 and to execute on our priorities, including additional RT-114 data by year-end.”

Talat Imran, Chief Executive Officer of Rani Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.